Education
About Us
Working with TipRanks
Follow Us
Context Therapeutics (CNTX)
NASDAQ:CNTX
CNTX Stock Chart & Stats
$1.60
$0.09(8.26%)
At close: 4:00 PM EST
$1.60
$0.09(8.26%)
Day’s Range― - ―
52-Week Range$0.49 - $2.00
Previous CloseN/A
Volume293.07K
Average Volume (3M)1.14M
Market Cap
$147.01M
Enterprise Value$15.42M
Total Cash (Recent Filing)$76.94M
Total Debt (Recent Filing)$140.20K
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Mar 25, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding91,879,170
10 Day Avg. Volume2,057,080
30 Day Avg. Volume1,136,077
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-2.09
Enterprise Value/Market Cap0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.79K
Enterprise Value/Ebitda-0.53
Forecast
1Y Price Target
$5.25Price Target Upside228.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyInitial RECIST-confirmed partial response in a platinum-resistant ovarian cancer patient indicates CTIM-76 can produce meaningful antitumor activity in heavily pre-treated tumors even below the intended target dose.
Safety And Dose EscalationNo cytokine release syndrome above Grade 1, no dose-limiting toxicities observed, and a maximum tolerated dose not yet reached support continued dose escalation and suggest a manageable safety profile for broader development.
Upcoming Data And ValuationStrong capitalization and focused management execution, combined with company positioning for key Phase I CTIM-76 readouts in 2026, has prompted higher analyst confidence and a raised price target, highlighting potential share-price upside around upcoming data.
Bears Say
Context Therapeutics News
CNTX FAQ
What was Context Therapeutics’s price range in the past 12 months?
Context Therapeutics lowest stock price was $0.49 and its highest was $2.00 in the past 12 months.
What is Context Therapeutics’s market cap?
Context Therapeutics’s market cap is $147.01M.
When is Context Therapeutics’s upcoming earnings report date?
Context Therapeutics’s upcoming earnings report date is Mar 25, 2026 which is in 73 days.
How were Context Therapeutics’s earnings last quarter?
Context Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.088 by -$0.012.
Is Context Therapeutics overvalued?
According to Wall Street analysts Context Therapeutics’s price is currently Undervalued.
Does Context Therapeutics pay dividends?
Context Therapeutics does not currently pay dividends.
What is Context Therapeutics’s EPS estimate?
Context Therapeutics’s EPS estimate is -0.1.
How many shares outstanding does Context Therapeutics have?
Context Therapeutics has 91,879,170 shares outstanding.
What happened to Context Therapeutics’s price movement after its last earnings report?
Context Therapeutics reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.088. Following the earnings report the stock price went down -5.31%.
Which hedge fund is a major shareholder of Context Therapeutics?
Currently, no hedge funds are holding shares in CNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Context Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.25 (228.13% Upside)
$5.25 (228.13% Upside)
Blogger Sentiment
Bullish
CNTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 680.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.5%
Last 30 Days ▼ 27.5%
Last 30 Days ▼ 27.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.23%
12-Months-Change
Fundamentals
Return on Equity
-33.68%
Trailing 12-Months
Asset Growth
-8.22%
Trailing 12-Months
Company Description
Context Therapeutics
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
CNTX Stock 12 Month Forecast
Average Price Target
$5.25
▲(228.13% Upside)
Technical Analysis
Ownership Overview
1.35% Insiders
5.67% Mutual Funds
63.99% Other Institutional Investors
25.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---